Otava offers 29 Alzheimer’s disease Targeted Libraries designed with Ligand-based and Receptor-based approach. These libraries contain only drug-like compounds. All molecules have enhanced potential for CNS bioavailability. Filtering by polar surface area parameter (PSA) which discriminates CNS penetrating compounds, we selected only those compounds having increased blood-brain barrier (BBB) permeability.
In this collection of targeted libraries we included those activities which can be divided into two Alzheimer’s treatment categories: (i) disease-modifying treatments that target and reduce the secondary pathologies of the disease, leading to the cessation or the reversal of disease progression;
We hope that Otava Targeted Libraries can help scientists and pharmaceutical companies racing to develop treatments that address the underlying Alzheimer’s disease processes.
P.O. Box 88
Kyiv 187, 03187
# # #
OTAVA Ltd. is an international science-based chemical company founded in 1997. It has production laboratories and offices in Europe (Kiev, Ukraine) and North America (Toronto, Canada).